Biotech | October 29, 2021
NH TherAguix releases new batch for AGuIX
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
PEL will explore the PLI scheme and apply if its beneficial.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
